NASDAQ:TRAW Traws Pharma (TRAW) Stock Price, News & Analysis $1.48 +0.03 (+2.07%) Closing price 04:00 PM EasternExtended Trading$1.46 -0.02 (-1.28%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Traws Pharma Stock (NASDAQ:TRAW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Traws Pharma alerts:Sign Up Key Stats Today's Range$1.42▼$1.4950-Day Range$1.14▼$2.1852-Week Range$1.00▼$3.27Volume141,116 shsAverage Volume1.40 million shsMarket Capitalization$15.04 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingModerate Buy Company Overview Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Read More Traws Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreTRAW MarketRank™: Traws Pharma scored higher than 60% of companies evaluated by MarketBeat, and ranked 416th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingTraws Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialTraws Pharma has a consensus price target of $8.00, representing about 446.1% upside from its current price of $1.47.Amount of Analyst CoverageTraws Pharma has only been the subject of 2 research reports in the past 90 days.Read more about Traws Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Traws Pharma are expected to decrease in the coming year, from ($2.23) to ($2.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Traws Pharma is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Traws Pharma is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Traws Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.13% of the float of Traws Pharma has been sold short.Short Interest Ratio / Days to CoverTraws Pharma has a short interest ratio ("days to cover") of 0.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Traws Pharma has recently increased by 198.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTraws Pharma does not currently pay a dividend.Dividend GrowthTraws Pharma does not have a long track record of dividend growth. News and Social Media2.8 / 5News SentimentN/A News SentimentTraws Pharma has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Traws Pharma this week, compared to 2 articles on an average week.Search Interest8 people have searched for TRAW on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows8 people have added Traws Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership3.5 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $998,207.00 in company stock, which represents 6.7064% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Traws Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $998,207.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders14.00% of the stock of Traws Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions7.95% of the stock of Traws Pharma is held by institutions.Read more about Traws Pharma's insider trading history. Receive TRAW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRAW Stock News HeadlinesTraws Pharma (NASDAQ:TRAW) Downgraded to "Strong Sell" Rating by Wall Street ZenMay 30, 2026 | americanbankingnews.comTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease OutbreaksMay 27, 2026 | globenewswire.comSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their historic runs - says the SpaceX IPO is set for June 12 and could be the most anticipated market debut ever. Brown is showing investors how to legally claim a stake before the company goes public, ahead of what chief market strategist Shay Boloor called 'the craziest IPO in the history of the stock market.'June 4 at 1:00 AM | Brownstone Research (Ad)Traws Pharma Updates ATM Equity Offering Prospectus SupplementsMay 26, 2026 | tipranks.comTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsMay 15, 2026 | globenewswire.comTraws Pops on Hantavirus ResearchMay 9, 2026 | baystreet.caA hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gainsMay 9, 2026 | msn.comTraws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship OutbreakMay 8, 2026 | benzinga.comSee More Headlines TRAW Stock Analysis - Frequently Asked Questions How have TRAW shares performed this year? Traws Pharma's stock was trading at $1.13 at the start of the year. Since then, TRAW shares have increased by 29.6% and is now trading at $1.4650. How were Traws Pharma's earnings last quarter? Traws Pharma, Inc. (NASDAQ:TRAW) issued its earnings results on Friday, May, 15th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.39. Read the conference call transcript. When did Traws Pharma IPO? Traws Pharma (TRAW) raised $67 million in an IPO on Thursday, July 25th 2013. The company issued 5,166,667 shares at a price of $12.00-$14.00 per share. How do I buy shares of Traws Pharma? Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Traws Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Traws Pharma investors own include Clearside Biomedical (CLSD), Evofem Biosciences (EVFM), Palatin Technologies (PTN), Sirius XM (SIRI), Adverum Biotechnologies (ADVM) and Company Calendar Last Earnings5/15/2026Today6/04/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 8 days, TRAW's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRAW Previous SymbolNASDAQ:TRAW CIK1130598 Webwww.onconova.com Phone267-759-3680Fax267-759-3681Employees17Year FoundedN/APrice Target and Rating Average Price Target for Traws Pharma$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+440.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$9.17 million Net MarginsN/A Pretax Margin-710.83% Return on Equity-913.18% Return on Assets-133.88% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.43 Sales & Book Value Annual Sales$2.79 million Price / Sales5.39 Cash Flow$0.80 per share Price / Cash Flow1.86 Book Value($0.07) per share Price / Book-21.14Miscellaneous Outstanding Shares10,160,000Free Float8,735,000Market Cap$15.04 million OptionableNo Data Beta1.45 Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:TRAW) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredWhere did Vanguard quietly put $101 billion?Tech investor George Gilder spent 40 years identifying paradigm shifts before they went mainstream - flagging ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
